---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-006318"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:15:30.851622+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor

## Summary
- On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.
- Company is subject to a Mandatory Panel Monitor for one year; if non-compliance recurs, immediate delist with no cure period.
- Previous extensions from Aug 2023 to Aug 2024 to regain compliance; now resolved with heightened monitoring.

## SEC filing metadata
- accession: 0001683168-24-006318
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824006318/0001683168-24-006318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824006318/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-006318
- JSON: https://secwatch.observer/filing/0001683168-24-006318.json
- Plain text: https://secwatch.observer/filing/0001683168-24-006318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.